Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

166.15 -0.92 (-0.55%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,726,556
Open 166.63
Bid (Size) 166.15 (10)
Ask (Size) 167.50 (3)
Prev. Close 167.07
Today's Range 165.74 - 168.35
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates

Performance

YTD
+3.86%
+3.86%
1 Month
+4.08%
+4.08%
3 Month
+14.07%
+14.07%
6 Month
+6.36%
+6.36%
1 Year
+2.27%
+2.27%

More News

Read More
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock
Via Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
Via Benzinga
Exposures Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Via Benzinga
3 Safe Stocks with Safe Dividends for Your Portfolio
Via MarketBeat
Topics Economy
Exposures Economy
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Via The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Via Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Via Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Via The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.